Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioVie Inc. stock logo
BIVI
BioVie
$8.05
-5.0%
$10.47
$6.20
$75.00
$15.73M0.73186,093 shs94,203 shs
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
$1.71
+13.2%
$1.72
$0.99
$8.77
$76.62M2.71.68 million shs2.90 million shs
MediciNova, Inc. stock logo
MNOV
MediciNova
$1.27
+1.6%
$1.38
$1.12
$2.55
$61.31M0.436,480 shs21,808 shs
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$1.17
+3.5%
$1.19
$0.83
$5.39
$70M1.13732,856 shs351,139 shs
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioVie Inc. stock logo
BIVI
BioVie
+4.57%-9.02%-21.57%+6.81%+111.75%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
+1.34%-3.21%-39.11%+33.63%-80.03%
MediciNova, Inc. stock logo
MNOV
MediciNova
0.00%-1.57%-11.35%-6.37%-10.71%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-0.88%+4.63%-16.30%+14.67%-60.63%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
BioVie Inc. stock logo
BIVI
BioVie
0.8456 of 5 stars
0.04.00.00.02.70.00.6
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
1.532 of 5 stars
3.52.00.00.00.00.80.6
MediciNova, Inc. stock logo
MNOV
MediciNova
1.842 of 5 stars
3.82.00.00.00.00.80.0
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
1.6695 of 5 stars
3.41.00.00.01.80.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioVie Inc. stock logo
BIVI
BioVie
4.00
Strong BuyN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
3.00
Buy$14.43743.78% Upside
MediciNova, Inc. stock logo
MNOV
MediciNova
3.50
Strong Buy$7.00451.18% Upside
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
2.80
Moderate Buy$9.00669.23% Upside

Current Analyst Ratings Breakdown

Latest BIVI, PYXS, MNOV, and CABA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/16/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy ➝ Strong-Buy$6.00 ➝ $5.00
6/11/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$25.00
5/19/2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/16/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $13.00
5/15/2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$23.00 ➝ $25.00
4/9/2025
MediciNova, Inc. stock logo
MNOV
MediciNova
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/A$25.35 per shareN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/A$3.12 per shareN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
$1M62.29N/AN/A$1.07 per share1.19
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
$16.15M4.49N/AN/A$2.03 per share0.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioVie Inc. stock logo
BIVI
BioVie
-$32.12M-$7.910.00N/AN/A-100.88%-78.49%8/21/2025 (Estimated)
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$115.86M-$2.540.00N/AN/AN/A-78.29%-65.68%8/6/2025 (Estimated)
MediciNova, Inc. stock logo
MNOV
MediciNova
-$11.04M-$0.23N/AN/AN/AN/A-20.77%-19.68%8/6/2025 (Estimated)
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$77.33M-$1.590.00N/AN/AN/A-57.49%-45.17%8/13/2025 (Estimated)

Latest BIVI, PYXS, MNOV, and CABA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/21/2025Q1 2025
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
-$0.67-$0.71-$0.04-$0.71N/AN/A
5/15/2025Q1 2025
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
-$0.29-$0.35-$0.06-$0.35N/AN/A
5/13/2025Q1 2025
MediciNova, Inc. stock logo
MNOV
MediciNova
-$0.14-$0.06+$0.08-$0.06N/AN/A
5/12/2025Q3 2025
BioVie Inc. stock logo
BIVI
BioVie
-$3.20-$1.50+$1.70-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
BioVie Inc. stock logo
BIVI
BioVie
N/AN/AN/AN/AN/A
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/AN/AN/AN/AN/A
MediciNova, Inc. stock logo
MNOV
MediciNova
N/AN/AN/AN/AN/A
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioVie Inc. stock logo
BIVI
BioVie
N/A
9.31
9.31
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
3.96
3.96
MediciNova, Inc. stock logo
MNOV
MediciNova
N/A
17.66
17.66
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
N/A
7.75
7.75

Institutional Ownership

CompanyInstitutional Ownership
BioVie Inc. stock logo
BIVI
BioVie
4.59%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
N/A
MediciNova, Inc. stock logo
MNOV
MediciNova
9.90%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
39.09%

Insider Ownership

CompanyInsider Ownership
BioVie Inc. stock logo
BIVI
BioVie
2.39%
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
11.25%
MediciNova, Inc. stock logo
MNOV
MediciNova
13.60%
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
10.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioVie Inc. stock logo
BIVI
BioVie
101.86 million1.81 millionNo Data
Cabaletta Bio, Inc. stock logo
CABA
Cabaletta Bio
5050.74 million45.03 millionOptionable
MediciNova, Inc. stock logo
MNOV
MediciNova
1049.05 million42.38 millionOptionable
Pyxis Oncology, Inc. stock logo
PYXS
Pyxis Oncology
6061.95 million55.38 millionOptionable

Recent News About These Companies

Pyxis Oncology Inc News (PYXS) - Investing.com
Stifel Nicolaus Keeps Their Buy Rating on Pyxis Oncology (PYXS)
RBC Capital Remains a Buy on Pyxis Oncology (PYXS)
Pyxis Oncology reports FY24 EPS ($1.32), consensus ($1.09)

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioVie stock logo

BioVie NASDAQ:BIVI

$8.05 -0.42 (-4.96%)
Closing price 04:00 PM Eastern
Extended Trading
$8.19 +0.14 (+1.74%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Cabaletta Bio stock logo

Cabaletta Bio NASDAQ:CABA

$1.71 +0.20 (+13.25%)
Closing price 04:00 PM Eastern
Extended Trading
$1.73 +0.02 (+1.23%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

MediciNova stock logo

MediciNova NASDAQ:MNOV

$1.27 +0.02 (+1.60%)
As of 03:59 PM Eastern

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.

Pyxis Oncology stock logo

Pyxis Oncology NASDAQ:PYXS

$1.17 +0.04 (+3.54%)
Closing price 04:00 PM Eastern
Extended Trading
$1.16 -0.01 (-0.85%)
As of 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.